PHARMA TECH

Tranquilmoney Releases PharmTracker for Independent Pharmacies, Small and Medium Pharmacy Chains

Tranquilmoney | December 28, 2020

Tranquilmoney, Inc., an organization that oversaw drug store outsider case compromise for Costco Pharmacy for more than 20 years, has delivered an electronic adaptation of its product. Any drug store would now be able to join to PharmTrackerTM and begin utilizing the framework to handle their cases.

Tranquilmoney has overseen over $1 billion per year in drug store receivables compromise with 100% compromise and 99.9% assortments. Industry guidelines of assortment are about 92.5%.

Dr. Karun Philip, Chairman and CEO, says "Drug store claims are moderately little with a normal of $40 from the protection plans. More than 20 years, we built up a framework that consolidated Artificial Intelligence, enormous information stockrooms, and area specialists, that in blend permit us to coordinate each installment to its relating guarantee. Thusly, all non-installments are recognized, and an underpayment of even one penny is identified and can be rebilled."

PharmTrackerTM can be utilized as a self-administration programming on the web or as a reevaluated administration. Utilizing Tranquiilmoney's framework will help a Pharmacy gather as much as 99.9% from protection, more than the business standard of about 92.5%.

Tranquilmoney expenses start at 45 pennies for every case for at least 3000 cases for each month going down to 2 pennies a case for bigger volumes. Here is the finished value list.

Spotlight

Pharmaceutical manufacturers are always dealing with the conflict of increasing productivity whilst following safe processes to produce safe products. Having an effective, reliable and outstandingly performing checkweighing system in place can reduce risks and help manufacturers in providing process safety in their daily production.

Spotlight

Pharmaceutical manufacturers are always dealing with the conflict of increasing productivity whilst following safe processes to produce safe products. Having an effective, reliable and outstandingly performing checkweighing system in place can reduce risks and help manufacturers in providing process safety in their daily production.

Related News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Telix Pharmaceuticals Limited | September 07, 2020

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform. Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate imaging is able to be an integral part of radiation treatment planning.

Read More

PHARMA TECH

Moderna hitches a ride with Uber to boost vaccine confidence—and, of course, drive access

Moderna | January 15, 2021

COVID-19 vaccine maker Moderna is looking for a lift from Uber—a collaboration lift, that is. The two companies say they're planning to work together to promote vaccine confidence and ease access to coronavirus shots. Early ideas include promoting vaccine safety on the Uber network and through in-app messages as well as incorporating Uber rides into the vaccination scheduling process. While those details are still in the works, the appeal of Uber as a partner for Moderna is not only its nationwide network and connections but also the diversity of its 1.2 million drivers. “Uber has broad access across the United States—its ride-sharing platform is used by Americans everywhere, and its drivers represent a wide variety of the population," Michael Mullette, Moderna's vice president of commercial operations in North America, said. "There’s a great opportunity for us to think about educating the population about how do you get immunized … but also how do you access credible information about vaccines." The deal comes amid a U.S. vaccine rollout hobbled by confusion, lack of centralized government planning and distribution headaches. Even when vaccines are readily available and easy to access, fear is hampering uptake, thanks to the unprecedented speed of vaccine development, historical abuse of the Black community in biomedical research and more generalized anti-vaxxer sentiment. Last month, Uber pledged 10 million free or discounted rides for underserved populations who may have difficulty with transportation to get vaccines. The company is partnering with the National Urban League, the Morehouse School of Medicine and the National Action Network to focus on communities of color where people have been disproportionately affected by COVID-19.

Read More

RESEARCH

Two Labs, an Envision Pharma Group Company Acquires Riparian

Two Labs | July 08, 2021

Two Labs, an industry-leading pharma services company and a subsidiary of Envision Pharma Group, announced today the acquisition of Riparian, a pharma consulting and SaaS company that assists manufacturers with pricing regulations, reporting, strategies, and program operations. The acquisition expands Two Labs' pharma service offerings, allowing the company to offer greater insights into the financials associated with drug launch and management, better positioning manufacturers for long-term success. In addition, Riparian's in-depth knowledge of government pricing regulations and program operations, combined with their consulting, business process outsourcing, and software capabilities, enables clients to understand the financials of their drug better, ensuring that the prices reported to the government are in accordance with the current government statutes and regulations. Riparian and Two Labs will collaborate to accelerate parent company Envision Pharma Group's plans for expansion in the growing biotech pharma sector in the United States. In November 2020, Envision acquired Two Labs. Riparian will continue to operate from its current headquarters in Henderson, Nevada, with offices in Pasadena, California, and Johnson City, Tennessee. In addition, David Chan and Cynthia Hwang, co-founders, will continue with the company. About Two Labs Two Labs is a leading pharmaceutical services company that offers pharmaceutical manufacturers a range of market access, market intelligence, and commercialization services. Two Labs has managed over 200 new product launches and over 290 in-market projects from pre-launch through loss of exclusivity since its start in 2003. About Envision Pharma Group Envision Pharma Group, founded in 2001, is a global, innovative technology and scientific communications company that serves pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) with applications in various areas of medical affairs and related functional responsibility. Envision Pharma Group serves over 90 companies, including all top 20 pharmaceutical companies, with services and technology solutions. About Riparian Riparian is a pharma Consulting, Outsourcing, and SaaS company based in Henderson, Nevada, assisting manufacturers in navigating government pricing regulations, reporting, strategies, and program operations. Riparian is a rapidly growing, innovative company supported by a team of industry experts.

Read More